candesartan cilexetil has been researched along with Arrhythmias, Cardiac in 5 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Arrhythmias, Cardiac: Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "trans-1,2-Cyclohexanediol, the major metabolite of the cilexetil moiety of candesartan cilexetil (CC), has been reported to have potent pro-arrhythmic effects in dogs with congestive heart failure (CHF), especially when co-administered with digoxin." | 7.72 | Absence of interactive effects of trans-1,2-cyclohexanediol, a major metabolite of the side-chain of candesartan cilexetil, on digoxin-induced arrhythmias in dogs. ( Chatani, F; Kitayoshi, T; Nishimura, S; Watanabe, T; Yamamoto, K, 2003) |
| "To evaluate the preventive effect of regression of left ventricular hypertrophy (LVH) on sudden cardiac death (SCD), the incidence of ventricular tachycardia or ventricular fibrillation (VT/Vf) after left coronary artery occlusion in Langendorff preparations was studied in the following five groups: (1) spontaneously hypertensive rats (SHR) without treatment (SHR-N), (2) SHR treated with captopril (SHR-C), (3) SHR treated with the angiotensin II receptor antagonist TCV-116 (SHR-A), (4) SHR treated with hydralazine (SHR-H), and (5) Wistar-Kyoto (WKY) rats." | 7.69 | Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade. ( Kanno, M; Kitabatake, A; Kohya, T; Nakaya, H; Saito, H; Tohse, N; Yokoshiki, H, 1995) |
| "trans-1,2-Cyclohexanediol, the major metabolite of the cilexetil moiety of candesartan cilexetil (CC), has been reported to have potent pro-arrhythmic effects in dogs with congestive heart failure (CHF), especially when co-administered with digoxin." | 3.72 | Absence of interactive effects of trans-1,2-cyclohexanediol, a major metabolite of the side-chain of candesartan cilexetil, on digoxin-induced arrhythmias in dogs. ( Chatani, F; Kitayoshi, T; Nishimura, S; Watanabe, T; Yamamoto, K, 2003) |
| " cefotiam hexetil) and an antihypertensive agent (candesartan cilexetil), were examined in beagles that were made congestive heart failure (CHF) by rapid ventricular pacing." | 3.71 | Cardiotoxic interaction of metabolites from a prodrug segment cilexetil (cyclohexyloxy-carbonyloxy-ethyl) with digoxin in the canine failing heart. ( Kakizoe, E; Okunishi, H; Shimoura, K; Wang, DQ, 2002) |
| "To evaluate the preventive effect of regression of left ventricular hypertrophy (LVH) on sudden cardiac death (SCD), the incidence of ventricular tachycardia or ventricular fibrillation (VT/Vf) after left coronary artery occlusion in Langendorff preparations was studied in the following five groups: (1) spontaneously hypertensive rats (SHR) without treatment (SHR-N), (2) SHR treated with captopril (SHR-C), (3) SHR treated with the angiotensin II receptor antagonist TCV-116 (SHR-A), (4) SHR treated with hydralazine (SHR-H), and (5) Wistar-Kyoto (WKY) rats." | 3.69 | Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade. ( Kanno, M; Kitabatake, A; Kohya, T; Nakaya, H; Saito, H; Tohse, N; Yokoshiki, H, 1995) |
| "Candesartan cilexetil-treated banded rat hearts displayed shorter QT intervals and lower vulnerability to atrial and ventricular tachyarrhythmias than vehicle-treated banded hearts." | 1.72 | Candesartan Cilexetil Attenuates Arrhythmogenicity Following Pressure Overload in Rats via the Modulation of Cardiac Electrical and Structural Remodeling and Calcium Handling Dysfunction. ( Chang, GJ; Chen, WJ; Ko, YS; Lai, YJ; Lee, YS; Yeh, YH, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, GJ | 1 |
| Yeh, YH | 1 |
| Chen, WJ | 1 |
| Ko, YS | 1 |
| Lai, YJ | 1 |
| Lee, YS | 1 |
| Okunishi, H | 1 |
| Shimoura, K | 1 |
| Wang, DQ | 1 |
| Kakizoe, E | 1 |
| Yamamoto, K | 1 |
| Kitayoshi, T | 1 |
| Nishimura, S | 1 |
| Chatani, F | 1 |
| Watanabe, T | 1 |
| Kohya, T | 1 |
| Yokoshiki, H | 1 |
| Tohse, N | 1 |
| Kanno, M | 1 |
| Nakaya, H | 1 |
| Saito, H | 1 |
| Kitabatake, A | 1 |
| Jalowy, A | 1 |
| Schulz, R | 1 |
| Heusch, G | 1 |
1 review available for candesartan cilexetil and Arrhythmias, Cardiac
| Article | Year |
|---|---|
AT1 receptor blockade in experimental myocardial ischemia/reperfusion.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Ca | 1999 |
4 other studies available for candesartan cilexetil and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Candesartan Cilexetil Attenuates Arrhythmogenicity Following Pressure Overload in Rats via the Modulation of Cardiac Electrical and Structural Remodeling and Calcium Handling Dysfunction.
Topics: Animals; Arrhythmias, Cardiac; Atrial Remodeling; Benzimidazoles; Biphenyl Compounds; Calcium; Hyper | 2022 |
Cardiotoxic interaction of metabolites from a prodrug segment cilexetil (cyclohexyloxy-carbonyloxy-ethyl) with digoxin in the canine failing heart.
Topics: Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Benzimidazoles; Biphenyl Compounds; Cardiac | 2002 |
Absence of interactive effects of trans-1,2-cyclohexanediol, a major metabolite of the side-chain of candesartan cilexetil, on digoxin-induced arrhythmias in dogs.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Benzimidazoles; Biphenyl Compounds; Cyclohexanols; | 2003 |
Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade.
Topics: Angiotensin II; Animals; Arrhythmias, Cardiac; Benzimidazoles; Biphenyl Compounds; Body Weight; Capt | 1995 |